Key Points
- Director Patricia Allen purchased 4,160 shares of Zenas BioPharma on Feb. 13 at an average price of $26.36 per share (total ~$109,657.60), raising her direct stake to 19,860 shares — a 26.5% increase; the trade was disclosed in an SEC filing.
- Zenas BioPharma stock opened at about $26.40, trades in a 12‑month range of $6.11–$44.60, has a market cap of ~$1.42 billion and a negative P/E, recently reported an EPS miss (‑$1.22 vs. est. ‑$0.87), while analysts hold a consensus "Moderate Buy" with an average target near $43.14.
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) Director Patricia Allen acquired 4,160 shares of Zenas BioPharma stock in a transaction that occurred on Friday, February 13th. The stock was bought at an average cost of $26.36 per share, with a total value of $109,657.60. Following the acquisition, the director directly owned 19,860 shares of the company's stock, valued at approximately $523,509.60. This trade represents a 26.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Zenas BioPharma Price Performance
Shares of NASDAQ:ZBIO opened at $26.40 on Friday. Zenas BioPharma, Inc. has a 12 month low of $6.11 and a 12 month high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The stock's 50 day moving average price is $27.56 and its 200 day moving average price is $25.58. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.35).
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of ZBIO. GF Fund Management CO. LTD. acquired a new stake in shares of Zenas BioPharma during the 4th quarter valued at about $38,000. Quarry LP raised its position in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company's stock valued at $25,000 after acquiring an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Zenas BioPharma during the third quarter valued at approximately $30,000. CWM LLC lifted its stake in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company's stock valued at $79,000 after acquiring an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Zenas BioPharma in the fourth quarter worth approximately $95,000.
Wall Street Analyst Weigh In
ZBIO has been the topic of several analyst reports. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday. Morgan Stanley downgraded shares of Zenas BioPharma from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Wedbush reaffirmed an "outperform" rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Finally, Citigroup lifted their price target on Zenas BioPharma from $27.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, October 28th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma presently has a consensus rating of "Moderate Buy" and an average target price of $43.14.
Read Our Latest Stock Report on Zenas BioPharma
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
